Acid Suppression Medications Linked to Serious Gastrointestinal Infections

Article

In a population-based study from Scotland, use of commonly-prescribed acid suppression medications such as proton pump inhibitors (PPIs) was linked with an increased risk of intestinal infections with C. difficile and Campylobacter bacteria, which can cause considerable illness.

Compared with individuals in the community who did not take acid suppression medications, those who did had 1.7-times and 3.7-times increased risks of C. difficile and Campylobacter, respectively. Among hospitalized patients, those using the medications had 1.4-times and 4.5-times increased risks, respectively.

Although acid suppression therapy is often considered relatively free from side effects, the findings suggest that there are significant adverse gastrointestinal consequences of their use. "Users of these medications should be particularly vigilant about food hygiene as the removal of stomach acid makes them more easily infected with agents such as Campylobacter, which is commonly found on poultry," said professor Thomas MacDonald, senior author of the British Journal of Clinical Pharmacology study.

Source: Wiley

Recent Videos
Ambassador Deborah L. Birx, MD, senior fellow of the George W. Bush Presidential Center
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Isis Lamphier, MPH, MHA, CIC; Tori Whitacre Martonicz, MA; and Heather Stoltzfus, MPH, RN, CIC, at APIC Conference and Expo 2024 (Photo courtesy of Tori Whitacre Martonicz)
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
Related Content